Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation

British Journal of Cancer

Volumn 74, Issue SUPPL. XXVII, 1996, Pages

  McKeown, S R ^a   Friery, O P ^a   McIntyre, I A ^a   Hejmadi, M V ^a   Patterson, L H ^b   Hirst, D G ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

AQ4N; Radiation; Therapeutic gain; Tirapazamine

Indexed keywords

1,4 BIS((2 (DIMETHYLAMINO N OXIDE)ETHYL)AMINO) 5,8 DIHYDROXYANTHRACENE 9,10 DIONE; 1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; ANTHRAQUINONE; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; MITOMYCIN C; TIRAPAZAMINE; UNCLASSIFIED DRUG; ANTHRAQUINONE DERIVATIVE; RADIOSENSITIZING AGENT; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; INTRAPERITONEAL DRUG ADMINISTRATION; IONIZING RADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REDUCTION; SWEAT GLAND; TOXICITY; ANIMAL; ARTICLE; DOSE RESPONSE; EXPERIMENTAL NEOPLASM; MULTIMODALITY CANCER THERAPY;

ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; NEOPLASMS, EXPERIMENTAL; RADIATION-SENSITIZING AGENTS; TRIAZINES;

EID: 0029885455     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. BROWN JM AND LEMMON MJ. (1991). Tumour hypoxia can be exploited to preferentially sensitize tumours to fractionated irradiation. Int. J. Radiat. Oncol. Biol. Phys., 20, 457-461.
2. JOHNS H, MORRIS WJ AND JOINER MC. (1995). Radiation response of murine eccrine sweat glands. Radiother. Oncol., 36, 56-64.
3. JUDAS L, BENTZEN SM, JOHNS H, JOINER MC AND MORRIS WJ. (1995). Time evolution of the number of functional murine eccrine sweat glands after irradiation: a quantitative analysis of experimental data using a model of proliferative and functional organization. Int. J. Radiat. Biol., 67, 565-575.
4. MCALEER JJA, MCKEOWN SR, MACMANUS MP, LAPPIN TRJ AND BRIDGES JM. (1992). Hypobaric hypoxia: a method for testing bioreductive drugs in vivo. Int. J. Radiat. Oncol. Biol. Phys., 23, 551-555.
5. MCKEOWN SR, HEJMADI MV, MCINTYRE IA, MCALEER JJA AND PATTERSON LH. (1995). AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br. J. Cancer, 72, 76-81.
6. PATTERSON LH. (1993). Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metast. Rev., 12, 119-134.
7. RAUTH AM, MOHINDRA JK AND TANNOCK IF. (1993). Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo. Cancer Res., 43, 4154-4158.
8. TROTTER MJ, CHAPLIN DJ AND OLIVE PL. (1990). Possible mechanisms for intermittent blood flow in the murine SCCVII carcinoma. Int. J. Radiat. Biol., 60, 139-146.
9. WORKMAN P. (1992). Design of novel bioreductive drugs. In New Approaches in Cancer Pharmacology: Drug Design and Development, Workman, P. (ed.) pp. 63-74. Springer: Vienna.
10. WORKMAN P AND STRATFORD IJ. (1993). The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metast. Rev., 12, 73-82.